Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor plus ruxolitinib in JAK inhibitor-naive myelofibrosis
MOH_2023-11-20_013060Phase 3Active, not recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelofibrosis (MF) comparing Selinexor plus ruxolitinib with Placebo plus ruxolitinib (2 arms). Started Oct 2023; status: active, not recruiting.
02
Drugs
selinexorruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2023-11-20_013060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-20_013060.